Diabetic Ketoacidosis (DKA) - Pathophysiology

SECTION 1

Historical Context & Motivation

Before the discovery of insulin, a diagnosis of type 1 diabetes mellitus was essentially a death sentence, and diabetic ketoacidosis (DKA) was the terminal event for most patients. Physicians had observed the fruity breath odor, deep labored breathing, and progressive coma in young diabetic patients for centuries, yet the biochemical basis of the condition remained elusive until advances in endocrinology and clinical chemistry converged in the early twentieth century. Understanding the historical trajectory of DKA is essential because the milestones in its recognition, treatment, and prevention mirror the broader evolution of metabolic medicine and critical care.

1886 • Kussmaul Breathing Described

Adolf Kussmaul characterized the deep, labored respiratory pattern seen in advanced diabetic coma, linking it to systemic acidosis and providing clinicians with a critical bedside sign that is still used in DKA recognition today.

1921 • Discovery of Insulin

Frederick Banting and Charles Best isolated insulin from canine pancreatic extracts at the University of Toronto, transforming type 1 diabetes from a fatal disease into a manageable chronic condition and making DKA a survivable emergency.

1960s • Low-Dose Insulin Protocols

Pioneering work by Alberti and others demonstrated that continuous low-dose intravenous insulin infusions were safer and equally effective compared to large bolus regimens, significantly reducing iatrogenic hypoglycemia and hypokalemia during DKA treatment.

2009 • ADA Consensus Statement

The American Diabetes Association published a comprehensive consensus statement on the diagnosis and management of hyperglycemic crises, codifying standardized protocols for fluid resuscitation, insulin therapy, and electrolyte replacement that remain the foundation of current clinical practice.

Despite over a century of progress, DKA continues to carry a mortality rate of approximately 1–5% in developed countries and substantially higher in resource-limited settings, particularly among children and the elderly. The central question that DKA pathophysiology seeks to answer is deceptively straightforward: How does insulin deficiency cascade into life-threatening acidosis, dehydration, and electrolyte derangement, and how can these processes be systematically reversed? Mastering this question requires an integrated understanding of carbohydrate, fat, and protein metabolism, acid-base physiology, and renal compensatory mechanisms.

SECTION 2

Core Principles & Definitions

Diabetic ketoacidosis is defined by a clinical triad of hyperglycemia (blood glucose typically >250 mg/dL), metabolic acidosis (arterial pH <7.30 and/or serum bicarbonate <18 mEq/L), and ketonemia (elevated serum β-hydroxybutyrate ≥3 mmol/L). Although DKA is classically associated with type 1 diabetes mellitus, it can also occur in type 2 diabetes under conditions of severe physiological stress such as sepsis, surgery, or myocardial infarction, a presentation sometimes termed ketosis-prone type 2 diabetes. Understanding the foundational principles requires clarity on several interrelated metabolic concepts.

Insulin Deficiency

Absolute or relative lack of insulin removes the primary anabolic signal, halting glucose uptake into skeletal muscle and adipose tissue and unleashing hepatic gluconeogenesis and glycogenolysis.

Counter-Regulatory Excess

Elevated glucagon, catecholamines, cortisol, and growth hormone amplify hepatic glucose output and stimulate lipolysis, flooding the liver with free fatty acids for ketone body synthesis.

Ketogenesis

In the absence of insulin, free fatty acids undergo β-oxidation in hepatic mitochondria. Excess acetyl-CoA is shunted into ketone body production, generating acetoacetate, β-hydroxybutyrate, and acetone.

Osmotic Diuresis & Dehydration

Hyperglycemia exceeds the renal threshold for glucose reabsorption (~180 mg/dL), causing glucosuria and obligatory water and electrolyte losses that lead to profound dehydration averaging 5–7 liters in adults.

Anion-Gap Metabolic Acidosis

Ketone bodies are strong organic acids that dissociate at physiological pH, consuming bicarbonate buffers and producing a widened anion gap. The resulting acidemia impairs cardiac contractility, enzyme function, and oxygen delivery.

✦

KEY TAKEAWAY

Think of insulin as the traffic controller at a metabolic intersection. When the controller disappears, glucose piles up in the bloodstream because cells cannot take it in, while the body paradoxically acts as though it is starving — breaking down fat reserves at an unsustainable rate. The resulting flood of acidic ketone bodies is analogous to exhaust fumes from an engine running on the wrong fuel: initially compensated by the body's buffering systems, but ultimately overwhelming if the underlying fuel mismatch is not corrected.

SECTION 3

Visual Explanation — Pathophysiological Cascade

This flowchart illustrates the dual pathways of DKA development. The left branch traces the hyperglycemic cascade from increased hepatic glucose output through osmotic diuresis and dehydration. The right branch follows the ketogenic cascade from lipolysis through ketone body accumulation and bicarbonate consumption. Both pathways converge on the final common pathway of dehydration and metabolic acidosis that defines clinical DKA.

As illustrated in the diagram above, the pathogenesis of DKA proceeds along two interrelated but distinct metabolic arms. The hyperglycemic arm is driven by unopposed hepatic gluconeogenesis and glycogenolysis, compounded by impaired peripheral glucose uptake; glucose accumulates in the extracellular fluid and spills into the urine once the renal threshold is exceeded. The resulting osmotic diuresis obligates massive losses of water and electrolytes, producing the classic polyuria, polydipsia, and eventual hypovolemia. Simultaneously, the ketogenic arm is fueled by unrestrained hormone-sensitive lipase activity in adipose tissue, which releases free fatty acids into the circulation at rates that overwhelm normal oxidative pathways. Within hepatic mitochondria, excess acetyl-CoA is diverted into the ketogenesis pathway because oxaloacetate — which normally condenses with acetyl-CoA to enter the citric acid cycle — is being siphoned off for gluconeogenesis. The convergence of these two arms produces the hallmark triad: hyperglycemia, ketonemia, and anion-gap metabolic acidosis.

SECTION 4

Biochemical Mechanisms & Quantitative Framework

The Anion Gap — Quantifying Metabolic Acidosis

The anion gap (AG) is a calculated value that helps clinicians identify the presence of unmeasured anions in the serum — in the case of DKA, these unmeasured anions are primarily acetoacetate and β-hydroxybutyrate. Under normal conditions, the anion gap reflects the concentration of albumin and other unmeasured anionic species, typically ranging from 8 to 12 mEq/L. In DKA, the accumulation of ketoacid anions widens the gap, often to values exceeding 20 mEq/L, providing a quantitative measure of the severity of ketoacidosis.

SERUM ANION GAP

AG = [Na⁺] − ([Cl⁻] + [HCO₃⁻])

Where AG = anion gap (mEq/L), [Na⁺] = serum sodium, [Cl⁻] = serum chloride, [HCO₃⁻] = serum bicarbonate. Normal range: 8–12 mEq/L. In DKA, AG is typically >12 mEq/L due to unmeasured ketoacid anions.

Corrected Sodium — Accounting for Hyperglycemia

Hyperglycemia exerts significant osmotic effects, drawing water from the intracellular to the extracellular compartment and diluting serum sodium. The measured sodium concentration is therefore artifactually low, and clinicians must calculate a corrected sodium to assess the patient's true sodium status and guide fluid management decisions. This correction helps differentiate dilutional hyponatremia from true sodium depletion.

CORRECTED SODIUM (KATZ FORMULA)

Na⁺(corrected) = Na⁺(measured) + 1.6 × [(Glucose − 100) / 100]

Where Na⁺ is in mEq/L and Glucose is in mg/dL. For every 100 mg/dL increase in glucose above normal, the measured sodium decreases by approximately 1.6 mEq/L due to osmotic water shift. Some references use a correction factor of 2.4 mEq/L for glucose levels exceeding 400 mg/dL.

Effective Osmolality — Assessing Hyperosmolarity

EFFECTIVE SERUM OSMOLALITY

Osm(eff) = 2 × [Na⁺] + [Glucose] / 18

Where Osm(eff) is in mOsm/kg, [Na⁺] is in mEq/L, and [Glucose] is in mg/dL. BUN is excluded because urea freely crosses cell membranes and does not contribute to effective osmolality. Normal range: 275–295 mOsm/kg. DKA patients often present with Osm(eff) of 300–320 mOsm/kg.

⚠

Clinical Pearl: The Potassium Paradox

Despite significant total-body potassium depletion (typically 3–5 mEq/kg), patients with DKA often present with normal or even elevated serum potassium levels on admission. This paradox arises because insulin deficiency and acidemia both promote transcellular potassium shift from the intracellular to extracellular space. Once insulin therapy is initiated and acidosis begins to correct, potassium rapidly re-enters cells, and serum levels can plummet dangerously. Aggressive potassium replacement is therefore required in almost all DKA patients, and insulin should be withheld if the initial serum K⁺ is below 3.3 mEq/L.

SECTION 5

Severity Classification & Precipitating Factors

The severity of DKA is stratified according to the degree of acidosis, level of consciousness, and magnitude of biochemical derangement. The American Diabetes Association classifies DKA into mild, moderate, and severe categories, each carrying distinct management implications. This classification guides decisions about the intensity of monitoring, the care setting (emergency department versus intensive care unit), and the aggressiveness of therapeutic interventions.

Parameter	Mild DKA	Moderate DKA	Severe DKA
Arterial pH	7.25–7.30	7.00–7.24	<7.00
Serum HCO₃⁻ (mEq/L)	15–18	10–14	<10
Anion Gap	>10	>12	>12
Mental Status	Alert	Alert / Drowsy	Stupor / Coma
Serum Ketones	Positive	Positive	Positive

ADA classification of DKA severity based on biochemical and clinical parameters

Common Precipitating Factors — The 5 I's

The 5 I's represent the most common precipitating factors for DKA: Infection (most common, accounting for 30–50% of cases), Insulin non-compliance or insufficiency, Infarction (myocardial, cerebral, or mesenteric), Initial presentation of new-onset type 1 diabetes, and Iatrogenic or Intoxication causes such as corticosteroid use, sympathomimetic drugs, or SGLT2 inhibitors.

Identifying the precipitating factor is a crucial component of DKA management because failure to address the underlying trigger increases the risk of recurrence and prolongs the metabolic derangement. In approximately 10–20% of DKA presentations, no clear precipitant can be identified, emphasizing the importance of a systematic workup including infectious disease screening, cardiac biomarkers, and a thorough medication reconciliation. The emergence of euglycemic DKA in patients taking SGLT2 inhibitors has added a new dimension to the differential, as these patients may present with near-normal blood glucose levels yet have significant ketonemia and acidosis, making the diagnosis easily overlooked if glucose alone is used as a screening parameter.

SECTION 6

Worked Example — Clinical Case Analysis

A 22-year-old woman with a known history of type 1 diabetes mellitus presents to the emergency department with nausea, vomiting, abdominal pain, and Kussmaul respirations. She reports running out of her long-acting insulin three days ago. Her laboratory results on admission are: serum glucose 480 mg/dL, Na⁺ 128 mEq/L, K⁺ 5.6 mEq/L, Cl⁻ 92 mEq/L, HCO₃⁻ 8 mEq/L, arterial pH 7.12, serum β-hydroxybutyrate 8.2 mmol/L. Calculate the anion gap, corrected sodium, and effective osmolality, and classify the severity of her DKA.

Comprehensive DKA Assessment

1
Step 1 — Calculate the Anion Gap

Using the formula AG = [Na⁺] − ([Cl⁻] + [HCO₃⁻]), substitute the given values: AG = 128 − (92 + 8) = 128 − 100 = 28 mEq/L. The normal anion gap is 8–12 mEq/L, so this patient has a significantly elevated anion gap of 28 mEq/L, consistent with the accumulation of unmeasured ketoacid anions.

AG = 28 mEq/L (markedly elevated)
2
Step 2 — Calculate the Corrected Sodium

Using the Katz correction: Na⁺(corrected) = Na⁺(measured) + 1.6 × [(Glucose − 100) / 100]. Substituting: Na⁺(corrected) = 128 + 1.6 × [(480 − 100) / 100] = 128 + 1.6 × 3.8 = 128 + 6.08 ≈ 134 mEq/L. The corrected sodium of 134 mEq/L indicates mild true hyponatremia, confirming that the measured value of 128 largely reflects dilutional effects of hyperglycemia, with some component of genuine sodium depletion from osmotic diuresis.

Na⁺(corrected) ≈ 134 mEq/L
3
Step 3 — Calculate the Effective Osmolality

Using Osm(eff) = 2 × [Na⁺] + [Glucose] / 18: Osm(eff) = 2 × 128 + 480 / 18 = 256 + 26.7 ≈ 283 mOsm/kg. This value is near the upper end of normal (275–295 mOsm/kg), suggesting that although hyperglycemia contributes to osmolar load, the dilutional hyponatremia partially offsets the glucose-driven osmolality increase.

Osm(eff) ≈ 283 mOsm/kg
4
Step 4 — Classify Severity

According to the ADA classification: pH of 7.12 falls in the severe range (<7.00 is severe, but 7.00–7.24 is moderate — this patient is at 7.12, which is moderate-to-severe). HCO₃⁻ of 8 mEq/L is <10 mEq/L (severe). If the patient is drowsy or confused, this further supports severe classification. Given the profoundly low bicarbonate and acidemic pH, combined with ketonemia (β-hydroxybutyrate of 8.2 mmol/L), this presentation is best classified as severe DKA warranting ICU-level care.

Severe DKA — ICU admission indicated
5
Step 5 — Assess Potassium Status Before Initiating Insulin

The serum K⁺ of 5.6 mEq/L is elevated, but this reflects transcellular shifting due to insulin deficiency and acidosis, not true hyperkalemia. The total-body potassium is almost certainly depleted. Because K⁺ > 5.3 mEq/L, potassium replacement should be held initially, but insulin therapy can be started safely. Once K⁺ falls to 4.0–5.3 mEq/L (which it will quickly with insulin), add 20–30 mEq/L KCl to each liter of IV fluid. Monitor K⁺ every 1–2 hours.

K⁺ 5.6 mEq/L — Start insulin; hold K⁺ replacement until level falls below 5.3 mEq/L

SECTION 7

DKA versus Hyperosmolar Hyperglycemic State (HHS)

Diabetic ketoacidosis and hyperosmolar hyperglycemic state (HHS) represent the two extremes of the hyperglycemic crisis spectrum, though overlap syndromes are common. Distinguishing between them is clinically critical because their management priorities differ: DKA requires insulin as the cornerstone of therapy, while HHS demands aggressive volume resuscitation as the primary intervention. The fundamental pathophysiological distinction lies in the degree of residual insulin activity — patients with HHS typically retain enough endogenous insulin to suppress lipolysis and ketogenesis but not enough to prevent extreme hyperglycemia.

Feature	DKA	HHS
Typical Diabetes Type	Type 1 (can occur in type 2)	Type 2
Serum Glucose	>250 mg/dL (often 300–800)	>600 mg/dL (often >1000)
Serum Osmolality	Variable (often <320 mOsm/kg)	>320 mOsm/kg
Ketosis / Acidosis	Significant ketonemia; AG metabolic acidosis	Minimal or absent ketosis; no significant acidosis
Onset	Rapid (hours to 1–2 days)	Insidious (days to weeks)
Dehydration	Moderate (5–7 L deficit)	Severe (8–12 L deficit)
Mortality Rate	1–5%	10–20%
Primary Treatment Priority	Insulin infusion + fluids + K⁺	Aggressive volume repletion ± low-dose insulin

Comparison of DKA and HHS: key distinguishing features

✦

KEY TAKEAWAY

DKA and HHS can be understood as two expressions of the same fundamental problem — insufficient insulin action — but they differ in degree rather than kind. Consider a factory analogy: in DKA, the production line (insulin signaling) is completely shut down, so the factory burns alternative fuels (fats) that produce toxic byproducts (ketone bodies). In HHS, the production line is severely understaffed but not entirely abandoned — just enough workers remain to prevent the toxic fuel switch, but not enough to keep products (glucose) from piling up dangerously in the warehouse. Recognizing where a given patient falls on this spectrum is essential for tailoring the therapeutic approach.

SECTION 8

DKA Management & Resolution Criteria

The management of DKA rests on four simultaneous pillars: aggressive intravenous fluid resuscitation, continuous low-dose insulin infusion, potassium and electrolyte replacement, and identification and treatment of the precipitating cause. These interventions must proceed in parallel, with frequent reassessment of clinical and laboratory parameters to guide titration. A thorough understanding of the resolution criteria is equally important, as premature discontinuation of insulin infusion or inadequate transition to subcutaneous insulin are leading causes of DKA recurrence.

Management Pillar	Approach	Key Monitoring Points
Fluid Resuscitation	0.9% NaCl at 15–20 mL/kg/hr for the first hour, then 250–500 mL/hr adjusted by hemodynamic status; switch to 0.45% NaCl when corrected Na⁺ is normal or elevated	Urine output, heart rate, blood pressure, corrected sodium trend
Insulin Therapy	Regular insulin continuous IV infusion at 0.1–0.14 units/kg/hr; when glucose reaches 200–250 mg/dL, add dextrose to IV fluids and reduce insulin rate to 0.02–0.05 units/kg/hr	Hourly glucose; glucose should fall by 50–75 mg/dL per hour
Potassium Replacement	If K⁺ < 3.3: hold insulin, replace K⁺ at 40 mEq/hr until >3.3; if K⁺ 3.3–5.3: add 20–30 mEq/L to each liter of IV fluid; if K⁺ > 5.3: hold K⁺, recheck in 2 hours	Serum K⁺ every 1–2 hours; continuous cardiac monitoring for arrhythmias
Bicarbonate	Generally NOT recommended; consider only if pH < 6.9 (100 mmol NaHCO₃ in 400 mL H₂O with 20 mEq KCl over 2 hours)	Arterial pH; avoid paradoxical CNS acidosis from CO₂ diffusion

Four pillars of DKA management with monitoring protocols

Resolution Criteria

DKA is considered resolved when at least two of the following three criteria are met: serum glucose <200 mg/dL, serum bicarbonate ≥15 mEq/L, and venous pH >7.30. Additionally, the anion gap should be closed (≤12 mEq/L). Critically, the insulin infusion should not be discontinued until at least 1–2 hours after the first dose of subcutaneous insulin has been administered to allow adequate serum levels to develop and prevent rebound ketosis. This overlap period is one of the most common points of management failure, and its importance cannot be overstated. Transitioning patients to their home insulin regimen requires a multidose insulin protocol that includes both basal and prandial components, titrated to the patient's caloric intake and prior insulin requirements.

⚠

Cerebral Edema Warning

In pediatric DKA patients, overly aggressive fluid resuscitation or excessively rapid reduction in serum osmolality can precipitate cerebral edema, a devastating complication with mortality rates of 20–25%. The mechanism involves osmotic shifts of water into brain cells as extracellular osmolality falls. Fluid replacement in children should be more conservative (10–20 mL/kg bolus), glucose should not be lowered by more than 50–75 mg/dL per hour, and mental status must be monitored continuously during the first 24 hours.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain the pathophysiological basis for Kussmaul respirations in DKA. Why does the respiratory pattern change, and what compensatory mechanism does it represent?

Show answer

Kussmaul respirations — deep, labored breathing — represent the respiratory system's compensatory response to metabolic acidosis. As ketoacid anions accumulate and consume bicarbonate buffers, the arterial pH drops. Peripheral and central chemoreceptors detect the acidemia and stimulate the medullary respiratory center to increase both the rate and depth of ventilation. This hyperventilation lowers the partial pressure of CO₂ (PaCO₂), shifting the carbonic acid equilibrium (H₂CO₃ ⇌ CO₂ + H₂O) to the right and thereby reducing the hydrogen ion concentration. This is a form of respiratory compensation for primary metabolic acidosis, as described by Winter's formula: expected PaCO₂ = 1.5 × [HCO₃⁻] + 8 (±2).

Question 2: BASIC CALCULATION

A patient presents with the following labs: Na⁺ 130 mEq/L, Cl⁻ 90 mEq/L, HCO₃⁻ 10 mEq/L, glucose 560 mg/dL. Calculate: (a) the anion gap, (b) the corrected sodium, and (c) the effective osmolality.

Show answer

(a) AG = [Na⁺] − ([Cl⁻] + [HCO₃⁻]) = 130 − (90 + 10) = 30 mEq/L. This is markedly elevated (normal 8–12), consistent with significant ketoacid accumulation. (b) Na⁺(corrected) = 130 + 1.6 × [(560 − 100)/100] = 130 + 1.6 × 4.6 = 130 + 7.36 ≈ 137.4 mEq/L. The corrected sodium is normal, indicating that the measured hyponatremia is almost entirely dilutional. (c) Osm(eff) = 2 × 130 + 560/18 = 260 + 31.1 ≈ 291 mOsm/kg. This is near the upper limit of normal, reflecting the opposing effects of hyponatremia (decreasing osmolality) and hyperglycemia (increasing osmolality).

Question 3: INTERMEDIATE

A 45-year-old patient with type 2 diabetes is admitted with glucose of 190 mg/dL, pH 7.18, HCO₃⁻ 12 mEq/L, and β-hydroxybutyrate of 5.8 mmol/L. She takes empagliflozin (an SGLT2 inhibitor). How does this presentation differ from typical DKA, and what is the underlying mechanism?

Show answer

This is a case of euglycemic DKA, a condition increasingly recognized in patients taking SGLT2 inhibitors. Unlike typical DKA where glucose exceeds 250 mg/dL, SGLT2 inhibitors promote renal glucosuria by blocking glucose reabsorption in the proximal tubule, effectively lowering serum glucose even as ketogenesis proceeds. The lower glucose reduces osmotic diuresis somewhat but masks the severity of the metabolic derangement if glucose is used as the primary screening criterion. The ketogenic drive is maintained because SGLT2 inhibitors reduce insulin secretion (due to lower glucose) while simultaneously increasing glucagon release, shifting the insulin-to-glucagon ratio in favor of lipolysis and hepatic ketogenesis. Management follows standard DKA protocols with an emphasis on early dextrose-containing fluids, since glucose levels may fall rapidly. The SGLT2 inhibitor should be discontinued immediately.

Question 4: APPLIED

A DKA patient is started on IV insulin at 0.14 units/kg/hr. After 3 hours, blood glucose has decreased from 520 mg/dL to 480 mg/dL — a rate of only ~13 mg/dL per hour, which is below the expected 50–75 mg/dL/hr decline. Serum K⁺ is now 3.8 mEq/L. What are the possible reasons for the inadequate glucose response, and what adjustments should be made?

Show answer

Several factors may explain the inadequate glucose response. First and most commonly, inadequate fluid resuscitation can impair glucose clearance because dehydration reduces renal perfusion and therefore glucosuria, and it impairs peripheral insulin delivery. Ensure the patient has received appropriate volume and increase the infusion rate if hemodynamically appropriate. Second, check the insulin infusion setup for mechanical issues — disconnected tubing, infiltrated IV site, or adsorption of insulin to the IV tubing (though modern tubing is less prone to this). Third, consider whether the patient has an ongoing counter-regulatory hormone surge from an unidentified precipitant such as occult sepsis, which can produce severe insulin resistance. The insulin infusion rate may be doubled (to 0.28 units/kg/hr or an equivalent bolus of 0.14 units/kg followed by a rate increase). Regarding the K⁺ of 3.8 mEq/L: this has fallen into the 3.3–5.3 range, so 20–30 mEq KCl should be added to each liter of IV fluid if not already running, and K⁺ should be rechecked hourly.

Question 5: CRITICAL THINKING

During DKA resolution, a patient's anion gap has normalized to 10 mEq/L, glucose is 180 mg/dL, and pH is 7.34. However, the serum bicarbonate is only 14 mEq/L and the serum chloride has risen to 115 mEq/L (from 92 mEq/L on admission). Explain this acid-base pattern. Is the acidosis worsening, and should management change?

Show answer

This patient is exhibiting a non-anion-gap hyperchloremic metabolic acidosis (NAGMA), which is an expected and benign transitional phenomenon during DKA resolution. As ketoacid anions (β-hydroxybutyrate and acetoacetate) are metabolized and cleared, the anion gap closes. However, the kidneys have been excreting ketoanions in the urine as sodium and potassium salts during the DKA episode, effectively losing potential bicarbonate regeneration equivalents. Simultaneously, aggressive normal saline resuscitation delivers a large chloride load. The net effect is that the chloride 'replaces' the ketoanions in the unmeasured-anion calculation, maintaining a depressed bicarbonate even as the anion gap normalizes — a so-called 'hyperchloremic gap' or transition from AG to non-AG acidosis. The pH of 7.34 is nearly normal and the clinical trajectory is improving, so the acidosis is not worsening in a clinically meaningful sense. The bicarbonate will gradually self-correct over 24–48 hours as renal tubular cells regenerate bicarbonate. No change in management is needed beyond continuing the current protocol and ensuring adequate hydration. If there is concern, switching some of the IV fluid to a balanced crystalloid (e.g., lactated Ringer's) can reduce the exogenous chloride load.

SUMMARY

Lesson Summary — Diabetic Ketoacidosis

Summary

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia (>250 mg/dL), anion-gap metabolic acidosis (pH <7.30, HCO₃⁻ <18 mEq/L), and ketonemia. The pathogenesis proceeds along two interrelated arms: an insulin deficiency–driven hyperglycemic cascade (via unopposed gluconeogenesis and glycogenolysis) causing osmotic diuresis and volume depletion, and a ketogenic cascade fueled by unrestrained lipolysis and hepatic conversion of free fatty acids to β-hydroxybutyrate and acetoacetate.

Management centers on four simultaneous pillars: isotonic fluid resuscitation to restore circulating volume, continuous low-dose IV insulin to suppress lipolysis and ketogenesis, potassium replacement guided by serial monitoring (recognizing the potassium paradox of elevated serum K⁺ despite total-body depletion), and identification of the precipitating trigger. DKA is distinguished from hyperosmolar hyperglycemic state (HHS) by the presence of significant ketosis and acidosis, and resolution requires normalization of the anion gap, pH >7.30, and glucose <200 mg/dL — with a mandatory 1–2 hour overlap of IV and subcutaneous insulin to prevent rebound ketoacidosis.